5 mayo 2015
A 12-week dose of an investigational three-drug hepatitis C combination cured the virus in 93 percent of patients with liver cirrhosis who hadn’t previously been treated, according to a study. For most of the past 20 years, therapies for hepatitis C relied on interferon drugs, which require regular injections for as long as one year and trigger miserable, flu-like side effects that prompt many patients to quit the regimen. Some patients aren’t eligible for this treatment if they have anemia, low platelets or other conditions.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/W4J4KcZUP8Q/150505121316.htm
